ACRS
Aclaris Therapeutics, Inc.
0.89
USD
This page is just a preview of the data found in TrendSpider’s full version
Aclaris Therapeutics, Inc. stock is down -80.54% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 22.22% of the previous 8 November’s closed higher than October. In the last 10 Unusual Options Trades, there were 10 PUTs. 25% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 13 Nov 14:39 | 16 Feb, 2024 | 6.00 | 5452 | ||
| 13 Nov 14:41 | 16 Feb, 2024 | 6.00 | 5452 | ||
| 13 Nov 14:41 | 16 Feb, 2024 | 6.00 | 5452 | ||
| 13 Nov 14:42 | 16 Feb, 2024 | 6.00 | 5452 | ||
| 13 Nov 14:42 | 16 Feb, 2024 | 6.00 | 5452 | ||
| 13 Nov 14:55 | 17 Nov, 2023 | 5.00 | 1719 | ||
| 13 Nov 16:57 | 15 Dec, 2023 | 4.00 | 2205 | ||
| 13 Nov 18:05 | 15 Dec, 2023 | 4.00 | 2205 | ||
| 13 Nov 19:33 | 17 Nov, 2023 | 3.00 | 3243 | ||
| 17 Nov 20:25 | 17 Nov, 2023 | 3.00 | 2537 |
Aclaris Therapeutics, Inc. develops novel drug candidates for immune-inflammatory diseases in the United States. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa.
